These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19341184)

  • 1. Biological therapy of inflammatory bowel disease.
    Owczarek D; Cibor D; Szczepanek M; Mach T
    Pol Arch Med Wewn; 2009; 119(1-2):84-8. PubMed ID: 19341184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crohn's targeted therapy: myth or real goal?
    Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
    Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
    Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
    Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
    Tursi A
    Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 14. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
    Barrie A; Regueiro M
    Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel biologics in inflammatory bowel disease.
    Papachristou GI; Plevy S
    Gastroenterol Clin North Am; 2004 Jun; 33(2):251-69, ix. PubMed ID: 15177537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.